Press Release Belfort, February 21, 2017
Growth in performance indicators in absolute terms: o Sale: € 1.57 billion, up € 113 million (+7.8%), reflecting the incorporation of LISI MEDICAL Remmele (€ 45 million for 7 months) in particular; o Organic growth: +4.6%, driven by the three divisions; o EBIT up € 11 million (+7.5%), with operating margin in line with the strategic target of 10.0%; o Positive Free Cash-Flow* , up almost € 34 million at € 74 million. • Financial strength maintained: o Net debt / EBITDA ratio maintained below than 1, despite substantial capital expenditure programs (€ 120 million) and financial investments (€ 94 million) in 2016. • Net earnings per share up: +30.0%; • Proposed dividend: € 0.45 per share; • 2017 targets: to continue and consolidate performance over the long-term. February 21, 2017 – The LISI Board of Directors has met under the chairmanship of Mr. Gilles KOHLER and assessed the final financial statements for the period ended December 31, 2016. These will be submitted for approval to the Annual General Meeting of Shareholders on April 25, 2017. (…)
via LISI AGAIN ACHIEVES GROWTH TARGETS IN 2016 | Press Release